AMF Medical SA

AMF Medical SA was a Swiss medical technology company focused on simplifying diabetes management through its development of the Sigi™ Patch Pump. Founded in 2014 by Chairman Peter Ryser and Co-CEO Antoine Barraud, the firm operated from the EPFL Innovation Park in Lausanne. The company's journey culminated in a significant milestone when it was acquired by Tandem Diabetes Care, a global diabetes technology firm, in a deal finalized in January 2023. This acquisition represented a strategic move for Tandem to integrate a patch pump into its product portfolio and expand its market reach to serve a broader segment of individuals with both type 1 and type 2 diabetes.

The core of AMF Medical's work was the Sigi™ Insulin Management System, a product under development and not yet commercially available. In November 2021, the Sigi pump received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA), a recognition that expedites the review process for promising medical devices. The business model centered on the research and development of this patch pump, with the goal of eventually securing regulatory approval and commercializing the technology. The acquisition by Tandem shifted this strategy, integrating AMF's technology and team into Tandem's larger R&D and commercialization pipeline. The transaction was valued at up to CHF 200 million, including an initial strategic investment, a cash payment at closing, and further payments contingent on developmental and regulatory milestones, such as FDA clearance.

The Sigi™ patch pump was engineered to reduce the complexities of daily diabetes care. It features a semi-reusable and rechargeable design, differentiating it from fully disposable pumps and aligning with sustainability objectives by minimizing electronic and battery waste. A key selling point is its use of pre-filled, standard insulin cartridges, which eliminates the need for users to manually fill reservoirs with a syringe. The system comprises a reusable pump body and a disposable adhesive pad with an integrated cannula. Designed for interoperability, the Sigi pump can connect via Bluetooth to third-party continuous glucose monitors (CGMs) and smartphone apps, enabling automated insulin delivery (AID) and remote control. Its compact, lightweight, and ergonomic form factor was developed to offer greater discretion and convenience compared to many existing insulin delivery systems.

Keywords: AMF Medical, Sigi Patch Pump, Tandem Diabetes Care, insulin delivery, diabetes management, medtech, patch pump, continuous subcutaneous insulin infusion, automated insulin delivery, type 1 diabetes, type 2 diabetes, medical device, rechargeable pump, pre-filled insulin cartridges, FDA breakthrough device, wearable technology, diabetes technology, insulin management, Antoine Barraud, Peter Ryser, EPFL Innovation Park, closed loop system, CGM integration